Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ibudilast Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Ibudilast, Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

NCT01740414
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
MN-166 (50 mg) First, Placebo First
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

NCT03782415
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
Interventions
MN-166, Temozolomide
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast for the Treatment of Alcohol Use Disorder

NCT03594435
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ibudilast, Placebo oral capsule
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

NCT04054206
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MN-166
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

Development of Ibudilast for Alcohol Use Disorder

NCT02025998
View directory record Official record
Conditions
Alcohol Use Disorders
Interventions
Ibudilast, Matched placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal

NCT00723177
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
AV411, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast and Withdrawal-Related Dysphoria

NCT03489850
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ibudilast, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

NCT02714036
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ibudilast
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Patchogue, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Trial of Ibudilast for Methamphetamine Dependence

NCT01860807
View directory record Official record
Conditions
Methamphetamine Dependence, HIV Infection
Interventions
Ibudilast, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 3, 2026, 9:53 AM EDT
No Longer Available No phase listed Expanded access

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

NCT06743776
View directory record Official record
Conditions
ALS
Interventions
MN-166
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
U.S. locations
15
States / cities
Scottsdale, Arizona • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 9:53 AM EDT
Active, not recruiting Phase 2 Interventional

Ibudilast for Treating Alcohol Use Disorder

NCT05414240
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Alcoholism
Interventions
Ibudilast, Medical management, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

NCT03533387
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MN-166
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970
View directory record Official record
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04429555
View directory record Official record
Conditions
Pneumonia, Viral
Interventions
Ibudilast, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 3, 2026, 9:53 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MN-166, placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
10
States / cities
Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 3, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

NCT01982942
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
ibudilast, Placebo oral capsule
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 65 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 3, 2026, 9:53 AM EDT